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 ABSTRACT 
Biomaterial implantation induces the foreign body response (FBR). Development of 
longer-term implants relies on the thorough understanding of the FBR. The progression of the 
FBR is regulated by a number of biomolecules including cytokines, chemokines, and matrix 
metalloproteinases (MMPs). The nature of the FBR requires the spatial and temporal regulation 
of these mediators. MMPs are an extremely large and diverse group of enzymes that play key 
roles in regulating the FBR. Precise spatiotemporal regulation of MMPs defines their proteolytic 
activities. The aim of this project is to develop a new bioanalytical method to visualize the 
localization of active MMPs at the implant site in ex vivo tissue samples. 
 The localization of active MMP-2 and MMP-9 surrounding the implanted biomaterial in 
the ex vivo tissue sample was determined using MALDI imaging mass spectrometry. The 
MALDI imaging scheme employed a synthetic FRET substrate specific for MMP-2 and MMP-9. 
The intensity of the m/z value corresponding to the product of active MMP-2 and MMP-9 
digestion in each spectrum was extracted to produce a two-dimensional image showing the 
localization of active MMP-2 and MMP-9 in the ex vivo tissue sample. Fluorescence imaging 
was used as a complementary technique. 
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ABBREVIATIONS 
AEBSF   4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
APMA    p-aminophenylmercuricacetate 
CHCA    α-cyano-4-hydroxycinnamic acid 
DNP    2,4-dinitrophenyl 
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MALDI-TOF MS  Matrix-assisted laser desorption ionization-time-of-flight  
    mass spectrometry 
MCP-1   Monocyte chemoattractant protein-1 
MMPs    Matrix metalloproteinases 
MNGCs   Multinucleated giant cells 
O.C.T.    Optimum cutting temperature 
PES    Polyethersulfone 
RECK Reversion-inducing cysteine-rich protein with kazal motifs 
TGF-β    Transforming growth factor-β 
TIMPs    Tissue inhibitors of metalloproteinases 
TNF-α    Tumor necrosis factor- α
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1. RESEARCH SIGNIFICANCE AND BACKGROUND 
1.1.1 Biomaterials and the foreign body response  
Materials used in constructing medical devices such as biosensors, drug-eluting stents, 
artificial heart valves, and hip prosthesis with a functional life ranging from temporary use to 
permanent implantation are defined as biomaterials.
1,2
 The primary response of the nonspecific 
immune system evoked by implanted biomaterials is the foreign body response (FBR) or the 
foreign body reaction.
3
 
The FBR is present at the tissue/material interface throughout the in vivo lifetime of a 
medical device and is characterized by a sequence of events including nonspecific adsorption of 
blood and tissue fluid proteins to the biomaterial surface, formation of blood-based provisional 
matrix, adhesion of monocytes/macrophages, fusion of macrophages to form multinucleated 
giant cells (MNGCs), formation of granulation tissue, and eventually formation of fibrous 
capsule.
2,4
 The fibrous capsule confines the implanted biomaterial and prevents it from 
interaction with the implant site healthy tissue.
2
 In some cases, the events in the FBR  can render 
the biomaterial unfit for long-term use.
1
 
 Several major efforts to engineer biocompatible devices that can avoid the FBR have 
been unsuccessful due to lack of knowledge of the complex biological effectors of the FBR.
5
 It is 
therefore important to understand the biological nature of the FBR in order to improve the 
lifetime of the longer-term implanted biomaterial.
6
 The progression of the FBR is regulated by a 
number of mediators including cytokines, chemokines, and matrix metalloproteinases (MMPs) 
produced by inflammatory cells in the local environment. The outcome of the FBR requires the 
2 
 
spatial and temporal regulation of these mediators. The intricate relationship between the FBR 
and the expression of these mediators remains to be explored as it is poorly understood.
3
 
Information about these mediators would eventually aid in understanding the cascade of 
processes during the FBR and in developing improved long-term biomaterials.  
MMPs are a large and diverse group of enzymes (23 human MMPs) that play key roles in 
regulating the FBR.
7
 Several MMPs including MMPs -1,-2,-3,-7,-8,-9,-10, and    -12 are 
involved in different stages of the wound healing process.
8,9
 Differences in spatial, temporal, and 
inducible expression of MMPs indicate their unique roles.
10
 Precise spatiotemporal regulation of 
MMPs confines their diverse proteolytic activities to the necessary conditions and locations.
11
   
Few methods are available to determine the localization of active MMPs in biological 
samples. However, there is no multiplexed assay to visualize the localization of several active 
MMPs. The aim of this project is to develop a new bioanalytical method to visualize the 
localization of active MMP-2 and MMP -9 at the implant site in ex vivo tissue samples. In the 
future, this approach can be extended to visualize the localization of several active MMPs at the 
implant site in ex vivo tissue samples. 
1.1.2 Role of MMPs in the FBR  
During the onset of the FBR, coagulation causes the formation of a blood-based 
provisional matrix around the implanted biomaterial.
3
  In response to the cascade of molecular 
signals during the inflammatory response, leukocytes migrate through this extracellular matrix 
(ECM) to reach the inflammation site. Remodeling of the ECM is accomplished by the MMP 
family to facilitate the migration of leukocytes.
3,12
  
3 
 
Proteolytic MMPs play a role in modulating the adhesion and subsequent fusion of 
macrophages on the biomaterial surface. The macrophages and the foreign body giant cells 
adhered to the surface of the biomaterial can secrete active MMPs to modulate the FBR and 
wound healing.
13
 
Moreover, MMPs modulate signaling during the FBR. The ECM serves as a reservoir for 
various growth factors, and signaling molecules including cytokines, and chemokines. ECM 
remodeling releases these molecules resulting in the activation of phagocytes.
3
  
1.1.3 Role of MMPs in inflammation 
MMPs expression has been observed to increase in almost every human disease marked 
by the presence of inflammation.
14
 MMPs are modulators of inflammatory responses.
15
 MMPs 
can either enhance or dampen inflammatory response. MMPs can stimulate inflammation by 
cleaving the precursors of the pro-inflammatory cytokines TNF-α, IL-1β, and TGF-β.12,16 On the 
other hand, MMPs may downregulate inflammation by cleaving chemokines such as            
MCP-1/CCL2 into their receptor antagonizing mediators.
15,17
 Chemokines are a family of 
chemotactic proteins that facilitate leukocyte chemotaxis by creating a gradient that acts as a 
guidance signal for the migration of leukocytes.
12
 MMP mediated cleavage of chemokines might 
result in enhancement, inactivation, or antagonism of chemokine activities.
9
 Additionally, MMPs 
might also have an indirect effect on other proteinases that bind, retain, or concentrate 
chemokines in certain locations.
9,16
 
 
4 
 
1.1.4 MMPs 
  MMPs (also called as matrixins) are a family of structurally and functionally related zinc-
dependent endoproteinases that are collectively responsible for the degradation of extracellular 
matrix and non-matrix components during cellular migration and tissue remodeling.
11,18-20
 MMPs 
fall under the metzincin superfamily of metalloproteinases characterized by a catalytic zinc atom 
in the active site followed by a methionine containing Met-turn.
11,21
 Gross and Lapiere were the 
first to report about MMP-1 in an attempt to establish how a tadpole loses its tail during 
metamorphosis.
22
 To date, there are 24 vertebrate MMPs, and 24 human homologues with two 
duplicated genes encoding MMP-23.
11,23
 
MMPs are synthesized in an inactive pro-form (zymogens).
11
 Except MMP-23, all MMPs 
contain a signal peptide at the N-terminal that leads them to the secretory pathway.
11,24
 Then, 
MMPs can be secreted from the cell or anchored to plasma membrane, thereby confining their 
catalytic activity to membrane proteins and proteins in the secretory pathway or extracellular 
space.
11,16
 Several MMP family members such as MMP-1, MMP-2, MMP-11, and MMP-13 
were found as intracellular proteins, with unclear functions.
22-24
 A large number of MMPs are 
classified into four secreted classes namely collagenase, gelatinase, stromelysin, and matrilysin.
13
 
Seven MMPs are classified into one of the three membrane-bound classes: type I and type II 
transmembrane bound, and glycosylphosphatidylinositol (GPI) anchored.
13
 Seven MMPs are not 
classified in to any of the above categories. MMPs are known to perform multiple and 
overlapping functions.
13
 Table 1.1 shows the classifications of MMPs.
11,13
  
 
5 
 
Main Group Sub - Group MMPs 
 
Secreted 
MMPs 
Collagenases MMP-1, MMP-8, MMP-13, and MMP-18 
 
Gelatinases MMP-2, and MMP-9 
 
Stromelysins MMP-3, and MMP-10 
 
Matrilysins MMP-7, and MMP-26 
 
Other  
secreted 
MMPs 
__________ MMP-11, MMP-12, MMP-19, MMP-20, 
MMP-21, MMP-27, and MMP-28 
Membrane-
type MMPs 
 
Type I 
transmembrane 
MMP-14, MMP-15, MMP-16, and MMP-24 
Type II 
transmembrane 
MMP-23A, and MMP-23B 
GPI anchored MMP-17, and MMP-25 
 
 
Table 1.1 Classifications of MMPs
11,13
 
The structure of MMPs is composed of several conserved functional domains.
25
      
Figure 1.1 shows the domain structures of all MMPs.
26,27
 All MMPs have 3 domains in common:  
signal peptide for protein secretion, prodomain for functional regulation, and  catalytic domain 
for substrate processing.
12
 
 
 
  
 
6 
 
 
Figure 1.1 Domain structures of 24 vertebrate MMPs (Redrawn from references 26, 27) 
The prodomain is ~80 amino acids long and has a conserved sequence PRCXXPD 
(PHCXXPD in MMP-26), where X may be any amino acid.
28
 The cysteine residue within this 
sequence ligates with Zn
2+
 in the catalytic domain to maintain the proenzyme in a latent form.
25
 
With the exception of MMP-23, the latency of all MMPs is overcome by disruption of the Cys-
Zn
2+
 covalent bond in a “cysteine switch mechanism”.27,29,30 The catalytic domain has ~170 
7 
 
amino acids and a Zn
2+
 binding site HEXXHXXGXXH (where X may be any amino acid), in 
which the three histidine residues coordinate with the catalytic zinc ion.
31
 The catalytic domain 
also has a structural zinc ion and one or more calcium ions.
32
  
With the exception of MMP-7, MMP-23, and MMP-26, all MMPs contain a hemopexin-
like domain (~210 amino acids) that is connected to the catalytic domain by a proline-rich hinge 
region.
16,25,33
 The hemopexin domain contributes to substrate recognition, enzyme activation, 
protease localization, internalization, and degradation.
27,34
  
Fibroblasts, endothelial cells, and inflammatory cells including granulocytes, 
lymphocytes, mast cells, dendritic cells, and monocytes-macrophages are the major source of 
MMPs.
35
 MMPs are synthesized in an inactive pro-form (zymogens) and are activated by other 
MMP family members or by activators such as serine proteases.
36,37
 The activities of MMPs are 
tightly regulated at different levels namely gene activation and transcription, translation, latent 
enzyme secretion, proenzyme activation, cell surface localization, and inhibition by endogenous 
inhibitors like tissue inhibitors of metalloproteinases (TIMPs), reversion- inducing cysteine-rich 
protein with kazal motifs (RECK), thrombospondin, and α2-macroglobulin.10,12,25,35,37-40 The 
effect of  posttranslational modification on MMPs activity is not fully understood.
35
 
The proteolytic activities of MMPs influence cellular processes including cell 
proliferation, migration, and adhesion.
11
 Maintaining the equilibrium between extracellular 
matrix deposition and degradation is important for normal tissue development.
19
 The 
fundamental physiological processes that involve tissue remodeling, such as wound healing, 
angiogenesis, and fetal development depend on the controlled and concerted activity of 
8 
 
MMPs.
11,20
 Aberrant regulation of MMPs is implicated in a wide variety of disease states 
including tumor invasion and metastasis, arthritis, tissue ulceration, periodontitis, and 
atherosclerosis.
18,20
  
1.2 Methods to study the spatial localization of MMPs  
1.2.1 Immunohistochemical staining 
Two methods are available for performing immunohistochemical staining to identify 
MMPs in ex vivo tissue samples. The direct method is based on the direct application of a 
primary antibody to the processed tissue whereas the indirect method is based on the 
identification of an unlabeled primary antibody by a labeled secondary antibody. The latter 
method is more sensitive and is therefore preferred for the identification of MMPs in local tissue 
samples. A primary antibody that can specifically recognize the MMP species without cross-
reaction with other molecules is desired and therefore monoclonal antibodies are suitable for this 
purpose. Immunohistochemical staining is limited to a few MMPs because of the non-
availability of commercial antibodies specific for all rat MMPs. Nonspecific immunostaining is 
sometimes obtained in this method. Immunoassays and immunoblotting using tissue 
homogenates or tissue culture media are some of the other beneficial methods to validate the data 
and to avoid misinterpretation of false positive and false negative staining.
41
 However, these 
techniques provide quantitative information of total MMPs concentration, but cannot distinguish 
between pro, active, and TIMP-complexed (inactivated) forms of MMPs. 
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1.2.2 In situ zymography 
In situ zymography enables visualization of localized MMPs activities in tissue samples 
by contacting the tissue section with either a photographic emulsion containing gelatin or a 
fluorescence-labeled substrate.
42,43
 After the incubation period, the activity of MMPs can be seen 
as white spots in a dark background or as black spots in a fluorescent background.
43
 The 
technique is limited to MMPs-2, -7, and -9.
43
 
1.2.3 Fluorescence-based imaging  
Förster resonance energy transfer (FRET) MMPs substrates contain two fluorophores 
situated at a distance of less than 100 Å. The emission wavelength of the donor overlaps with the 
excitation wavelength of the acceptor and the donor can transfer energy to the acceptor in a non-
radiative fashion. Cleavage of the substrate by MMPs relieves the quenching and results in an 
increase in fluorescence intensity. The change in fluorescence intensity correlates with the 
activity of MMPs.
44
 The technique is limited by the number of fluorophores that can provide 
non-overlapping emission bands for the products of MMPs activity.  
1.2.4 Near Infrared (NIR) fluorescence imaging 
Quenched NIR fluorogenic MMPs substrates permit the noninvasive visualization of 
MMPs activity in whole animals. NIRF substrates were developed based on the FRET 
mechanism. Cleavage of the substrate by MMPs rescues the quenching and results in an increase 
in NIR fluorescence intensity.
44,45
 Higher penetration of photons emitted by the NIR 
10 
 
fluorophores, and low autofluorescence of the tissues in the NIR spectral region make this 
technique ideal for tissue imaging.
45
  
1.3 Imaging mass spectrometry (IMS) 
Immunohistochemistry and fluorescence microscopy are usually employed to image the 
localization of MMPs within a specific tissue section. Unlike the above-mentioned techniques, 
IMS uses molecular mass as the endogenous label thereby eliminating the need for special 
labeling agents.
46
 The localized distribution of active MMPs in ex vivo tissue samples can be 
visualized in an indirect manner by monitoring the products formed as a result of activity of 
MMPs on specific substrates using IMS. 
Imaging MS techniques provide information on the identity and spatial distribution of 
molecules of interest in tissue sections, and single cells.
47,48
 Low resolution MALDI-TOF MS 
images (50–500 µm) indicate the localization of the molecule in a tissue or organ whereas high 
resolution SIMS-TOF MS images (5–20 µm) provide information about sub-cellular localization 
of the molecule.
47
 
1.3.1 MALDI imaging MS (MALDI-IMS) 
Imaging mass spectrometry experiments can be performed on a MALDI-TOF mass 
spectrometer. Image reconstruction is achieved with custom-made software that also controls the 
movement of the sample stage over the specified area on the target plate. Sample preparation, 
sensitivity of the ionization step, spatial resolution, and the speed of the technique (laser 
repetition rate) influence the analyte localization information obtained using MALDI-IMS.
49
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1.3.2 MALDI-TOF instrumentation 
Matrix-assisted laser desorption ionization (MALDI) is a soft ionization technique in 
which the sample is co-crystallized with a solid matrix that absorbs at the wavelength of the 
laser. The gas-phase ions produced by irradiating the sample with a pulsed-laser are directed to 
the mass analyzer.
50
 
A time-of-flight (TOF) mass analyzer separates ions based on the differences in their 
velocities.
50
 Ions are accelerated from the ion source into the “field-free” drift region towards the 
detector. The TOF mass spectrometer measures the time required for an ion to travel from the 
ion source to the detector. During the instantaneous acceleration process, all the ions receive the 
same kinetic energy but have different velocities because of the difference in m/z values. The 
ions separate in to groups according to their velocity during their flight through the “field-free” 
region between the ion source and the detector. In the reflectron mode, an electrostatic mirror is 
used to reflect ions of the same m/z values but with small differences in kinetic energies to 
improve resolution.
51
 
1.3.3 MS/MS spectra using the LIFT technique 
MS/MS spectra were obtained using the “LIFT” technique in the MALDI- TOF/TOF 
mass spectrometer that produces fragment ions by unimolecular decay of the precursor ions 
without the use of collision gas. Ions coming out of the ion source are subjected to 8 kV 
accelerating voltage. Fragmentation occurs during the long flight time of the ions. The selected 
precursor and fragment ions are isolated using a timed ion selector. The ions are then subjected 
to a potential lift of 19 kV in the “LIFT” device and mass analyzed in a single spectrum.52 
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1.3.4 Working principle 
The tissue sample preparation step involves obtaining a thin tissue section of      5-20 µm 
thickness followed by thaw-mounting the section on to a precooled (-21
0
 C) MALDI target plate. 
Matrix is applied directly to the tissue and allowed to air-dry.
53
 A focused pulsed laser beam is 
rastered across the tissue section.
54
 A complete mass spectrum is acquired at specific (x, y) 
coordinates from the tissue using a TOF mass analyzer. Both the sampling location and the ions 
detected are recorded. The process is repeated in an ordered array across the tissue surface. The 
pixels representing the sampling positions are compiled to generate a picture image for each of 
the detected molecule. Any m/z signal is displayed with its relative intensity over the entire array, 
producing a density map of the molecule in the array area.
53
  
1.3.5 Tissue sample preparation                                                         
Tissue sample preparation is an important step in tissue analysis by MALDI imaging MS. 
The objective of the sample preparation step is to get MS-compatible tissue samples.
48
 Samples 
should be handled properly from the time of tissue harvest up to mass spectral analysis. 
Immediate snap-freezing of the dissected tissue prevents proteolytic degradation. Tissue sections 
of 10-20 µm thickness is normally used for imaging MS work. Ultra thin tissue sections can be 
very fragile and susceptible to tearing. Thicker tissue sections require longer drying times and 
affect the performance of the mass analyzer by their insulating properties.
47
 Limiting the 
thickness of tissue sections and avoiding the use of polymer embedding material during the 
cryomicrotome cutting of the tissue sections is desired. It is beneficial to deposit the tissue 
section on to a cold slide followed by rapidly warming the tissue and the slide (thaw mounting). 
13 
 
Sections should be completely thawed when mounted on to an ITO-coated glass slide to avoid 
freezer burn caused by the residual moisture. Tissue sections should be stored at -80
0
 C until 
analysis. 
48,55,56
 
In this research, placement of tissues on the sample holder without polymer embedding 
material was not possible because of the small size of the tissues. Tissues were maintained at the 
desired orientation on the sample holder by using optimum cutting temperature polymer. Great 
care was taken to keep the tissue surface polymer-free. In case of accidental contamination of the 
tissue surface with the polymer embedding material, the 70/30 v/v% ethanol/water wash would 
dissolve the polymer and keep the tissue surface polymer-free. 
1.3.6 Tissue washing step  
                The objective of the tissue washing step is to wash away contaminants such as optimum 
cutting temperature (O.C.T.) polymer as well as endogenous molecular species such as lipids and 
biological salts that might affect the ionization efficiency of the analytes of interest.
48,55
 
Segregation of salts from the matrix crystals will result in an inhomogeneous sample surface and 
these local variations can influence the ionization process.
48
 The MS signal quality and intensity 
are improved by the removal of lipids that negatively affect  the signal.
57
 It is presumed that the 
solvent washing step will precipitate most proteins in situ and  localize them within their cellular 
compartments.
55
 
A typical washing step involves the use of ice-cold 70-80% ethanol for the removal of 
salts. Organic solvents such as chloroform, acetone, hexane, toluene, xylene, and 
dichloromethane are known to remove lipids.
48
 But, there is lack of knowledge of the effect of 
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these solvents on enzyme activity. The different solvents that were tried in this study (70% 
ethanol, 80% methanol, and isopropanol) are known to preserve enzyme activity.  
1.3.7 Matrix selection and deposition 
Selection of an appropriate matrix can enhance the sensitivity of the MS technique 
towards specific molecules.
48
 Matrix deposition should result in homogeneous matrix crystals on 
the tissue surface without delocalizing the analytes. High resolution tissue imaging requires the 
formation of matrix crystals on the tissue surface with dimensions smaller than or equal to the 
diameter of the ionization laser beam. The matrix deposition method should be robust and 
reproducible.
48,49
 
1.3.8 Visualizing the spatial localization of active MMP-2 and MMP-9 
 
The conventional imaging techniques using fluorescence labels cannot be used to monitor 
the localization of several active MMPs due to the non-availability of longer wavelength 
fluorophores that provide non-overlapping emission bands for multiplexed MMPs activity. Most 
of the commercially available shorter wavelength FRET substrates cannot be used for ex vivo 
tissue imaging studies because of the higher autofluorescence of tissues at the wavelengths used. 
IMS is an emerging technique that eliminates the need for special labeled substrates since it uses 
molecular mass for identification.  
In this research, an indirect MALDI-IMS scheme that employed substrates specific for 
MMP-2 and MMP-9 was tested to visualize the spatial localization of active MMP-2 and MMP-9 
at the implant site in ex vivo tissue samples. This novel MALDI-IMS approach for monitoring 
the localization of active MMP-2 and MMP-9 can be extended to other MMPs by selecting 
15 
 
specific synthetic substrates, thus making this a multiplexed technique to visualize the 
localization of all active MMPs in ex vivo tissue samples. This opens up new possibilities for 
using IMS as a multiplexed imaging technique for several biological applications.  
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2. IN SITU STUDIES TO IMAGE THE SPATIAL LOCALIZATION OF                 
ACTIVE MMP-9 
2.1 Introduction 
Enzyme activity, which results in a mass difference between the substrate and its 
products, can be monitored by mass spectrometry.
58
 Initial studies were performed to image the 
in situ enzymatic activity of trypsin on cytochrome c using MALDI-TOF MS.  
MMPs have broad and overlapping substrate specificities towards their natural substrates. 
Synthetic MMPs substrates are advantageous in that they are more specific than the natural 
MMPs substrates.
59
 In this chapter, 2,4-dinitrophenyl(DNP)-Pro-Leu-Gly~Met-Trp-Ser-Arg, a 
self-quenched FRET peptide substrate specific for the gelatinases MMP-2 and MMP-9, was used 
for the in situ detection of MMP-9 activity using MALDI-TOF MS. The MMP-9 activity assay 
scheme is shown in Figure 2.1.  
GM-6001, a broad spectrum MMPs inhibitor was employed to achieve efficient 
inhibition of MMP-9 activity in situ.
60,61
 The inhibition of MMP-9 activity by GM-6001 is 
crucial to validate the assay scheme for in vivo detection of MMPs activity to rule-out proteolytic 
activities not related to MMPs. 
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Figure 2.1 MMP-9 activity assay scheme 
2.2 Experimental section 
2.2.1 Chemicals 
Trypsin (Trypsin gold, Mass spectrometry grade) was purchased from Promega (Promega 
US, Madison, WI, USA). Cytochrome c from bovine heart was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). MMP-9 (recombinant rat proenzyme, 94 kDa monomer, specific activity 
> 710 picomoles/min/µg) was purchased from R & D Systems Inc. (Minneapolis, MN, USA). 
DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg, p-aminophenylmercuricacetate, GM-6001 (Galardin or N-
[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide, a broad-
spectrum MMPs inhibitor), and acetonitrile were purchased from EMD chemicals (Gibbstown, 
NJ, USA).  QXL
TM
520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-carboxyfluorescein or     
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5-FAM)-NH2,  a longer wavelength FRET substrate specific for MMPs-1, -2, -8, - 9, -12, -13 and 
-14 was purchased from Anaspec (Fremont, CA, USA). Formic acid and HPLC grade water were 
purchased from Alfa Aesar (Ward Hill, MA, USA). Matrix chemicals, 2,5–dihydroxybenzoic 
acid (DHB), and α-cyano-4-hydroxycinnamic acid(CHCA) were purchased from Sigma-Aldrich 
(St. Louis, MO,USA). Indium tin oxide (ITO)-coated glass slides were purchased from Bruker 
Daltonics Inc. (Billerica, MA, USA). Stock solutions of DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg 
and QXL
TM
 520-Pro-Leu-Gly-Cys (Me)~His-Ala-D-Arg-Lys (5-FAM)-NH2 were prepared in 
DMSO. Further dilutions were carried out with the assay buffer (50 mM Tris at pH 7.5, 10 mM 
CaCl2, 1 µM ZnCl2, and 50 mM NaCl). 
Novex 10% zymogram (gelatin) gel (1.0 mm, 12 well), LDS sample buffer (4X), MES 
SDS running buffer (20X), simplyblue safestain (Coomassie G-250 stain), and XCell surelock 
mini cell system were purchased from Invitrogen (Carlsbad, CA, USA). Prestained protein 
ladder was purchased from New England Biolabs Inc. (Ipswich, MA, USA). All dilutions were 
made with HPLC-grade water. Zymography was performed according to the manufacturer’s 
instructions. 
2.2.2 (A) MALDI-TOF MS system 
Mass spectrometric analyses were performed in the reflectron, positive mode at 25 kV 
accelerating potential on a Reflex III MALDI-TOF mass spectrometer equipped with a pulsed 
nitrogen laser working at 337 nm at a laser repetition rate of 8.1 Hz (Bruker Daltonik, Bremen, 
Germany). The external calibration of the instrument was performed using a solution of peptide 
calibration standard II (Bruker Daltonics Inc., Billerica, MA,USA) containing angiotensin II, 
angiotensin I, bradykinin fragment 1-7, substance P, bombesin, ACTH clip 1-17, ACTH clip   
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18-39, and somatostatin 28, and DHB matrix solution {[M+H]
+
: 1046.5, 1296.7, 757.4, 1347.7, 
1619.8, 2093.1, 2465.2, 3147.5, and 137.0}. The matrix solution was sprayed using an in house-
built nebulizer.
62
 MS/MS spectra were obtained using the “LIFT” technique with a Bruker 
Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonik, Bremen, Germany). 
The analysis was performed using Bruker Flexanalysis 2.4 software. Mass spectral data 
sets were acquired using the Fleximaging software (Bruker Daltonik, Bremen, Germany) with a 
raster width of 600 µm. Each pixel composed of 300 individual laser shots collected in 50-shot 
increments from four positions within a single spot. Molecular images were visualized using the 
Fleximaging software.  
2.2.2 (B) Matrix selection and deposition 
Sinapinic acid (SA), 2,5-dihydroxybenzoic acid (DHB), and α-cyano-4-hydroxycinnamic 
acid (CHCA) are the conventional matrices for imaging MS.
46
 Sinapinic acid was not considered 
for this research as it is the matrix of choice for protein analysis in tissue sections.
49
 The 
matrices, α-cyano-4-hydroxycinnamic acid and 2,5-dihydroxybenzoic acid, were selected as they 
are well known for highest sensitivity in peptide analysis and for good signal intensity, 
respectively.
48
 The matrices were dissolved in acetonitrile/HPLC grade water (50/50 v/v%) 
containing 0.1% formic acid.  
High resolution tissue imaging requires homogeneous matrix deposition without inducing 
lateral migration of analytes.
49
 The matrix solution was sprayed over the tissue sections using a 
home-built nebulizer. The spray distance was optimized to avoid excessive wetting of tissue 
sections marked by dripping of matrix solution from the tissue sections, resulting in 
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delocalization of analytes. Multiple spray cycles of 150-200 µL were performed up to 8 times on 
a single tissue section from a distance of approximately 25 cm measured with a ruler. The total 
volume of the matrix solution per tissue section was 1.5 mL. Tissue sections on the glass slide 
were air-dried at room temperature for 5 minutes in between the spraying cycles. The time scale 
of the matrix spraying and drying process was 30 minutes.  
2.2.3 MALDI-TOF imaging MS for monitoring the in situ localization of trypsin enzymatic 
activity on ITO-coated glass slides 
The localization of trypsin on ITO-coated glass slides was studied using MALDI-TOF 
imaging MS. The matrix used was 1M 2,5-dihydroxybenzoic acid in acetonitrile/HPLC grade 
water (50/50 v/v%) containing 0.1% formic acid. The ITO-coated glass slides were marked with 
a white BIC wite-out shake-N squeeze correction pen (BIC USA Inc., Shelton, CT, USA). 
Digital images of the sample areas on the slides were acquired using the scanner of a HP Deskjet 
F4240 All-in-one printer at a resolution of 600 ppi (Hewlett-Packard Company, Palo Alto, CA, 
USA). 
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A uniform layer of cytochrome c (2 mg/mL) was applied to ~1 cm
2
 square area on the 
glass slide. Trypsin solution (0.2 mg/mL) was applied to the triangular region on the 1 cm
2 
square area. The glass slide was incubated in a humidity chamber at 37
0
C for 30 minutes. Peptide 
calibration standard II (2 µL) from Bruker Daltonics Inc. (Billerica, MA, USA) was spotted 
beside the 1 cm
2 
square area. The matrix solution was sprayed over the dried sample area using 
an in house-built nebulizer. Multiple spray cycles of approximately 300 µL were performed on 
the sample area. The total volume of the matrix solution per sample area was 3.0 mL. The 
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sample areas on the glass slide were air-dried at room temperature for 5 minutes in between the 
spraying cycles. The time scale of the matrix spraying and drying process was 30 minutes. 
Sample areas were analyzed using the MALDI-TOF mass spectrometer. The white-out dots were 
used to teach the software for selecting the imaging area by providing positional information.
63,64
 
2.2.4 (A) Activation of MMP-9 
MMP-9 was obtained in its proenzyme form and required activation using p-aminophenyl 
mercuric acetate (APMA). Recombinant rat MMP-9 is converted from a 94 kDa proenzyme to 
an 84 kDa active enzyme.
65
 Pro MMP-9 (530 pM) was incubated with 2.5 mM  APMA in                                             
assay buffer (50 mM Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and 50 mM NaCl) for 2 hours at 
37
0
C in a sand bath.  
2.2.4 (B) Zymography 
The activation state of MMP-9 was tested using zymography. An advantage of 
zymography is that both pro- and active- forms of MMP-9 can be distinguished on the basis of 
their molecular weight.
66
 
APMA-activated MMP-9 samples (25 nM) were mixed with SDS sample buffer and 
applied to 10% tris-glycine gels with 0.1% gelatin as the substrate. Electrophoresis was 
performed according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA) using 
XCell surelock mini-cell system at 100 V constant voltage for 130 minutes. After 
electrophoresis, gels were soaked for 1 hour in 2.5% Triton X-100 to remove SDS. Gels were 
incubated in zymogram developing buffer (50 mM Tris-HCl with 200 mM NaCl, 5 mM CaCl2, 
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and 0.02% Brij-35, pH 7.5) for 12 hours at 37
0
 C. After incubation, gels were stained with 
Coomassie G-250 stain for 1 hour and destained in 40/60 v/v% methanol/water with 10/90 v/v% 
acetic acid/water. Activities of MMP-9 were detected as clear zones against a blue background. 
In control experiments, GM-6001 (50 μM) was added to the incubation buffer to confirm that the 
gelatinolytic activity was because of MMP-9. The gels were scanned in a HP scanjet 8300 
professional image scanner (Hewlett-Packard Company, Palo Alto, CA, USA) after rinsing with 
water. 
2.2.5 Spectrofluorometer 
Fluorescence, resulting from enzymatic activity of MMP-9 on QXL
TM
 520-Pro-Leu-Gly-
Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2, was monitored in a Fluoromax-4 
spectrofluorometer (Horiba Jobin Yvon Inc., New Jersey, USA) at an excitation wavelength of 
490 nm and an emission wavelength of 520 nm.  
2.2.6 Fluorescence studies with QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys    
(5-FAM)-NH2 
The fluorescence intensity of 10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-
Lys(5-FAM)-NH2 was monitored in a spectrofluorometer at an excitation wavelength of 490 nm 
and an emission wavelength of 520 nm for 5 minutes.
67
 Active MMP-9 (4 nM) was added to    
10 µM  QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 and the increase 
in fluorescence intensity was monitored for 30 minutes (Figure 2.8).   
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2.2.7 MALDI-TOF MS studies with QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-
Lys(5-FAM)-NH2 
QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2, a longer 
wavelength FRET substrate suitable for fluorescence imaging studies, was tested for 
compatibility with MS. QXL
TM 
520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 
(10 µM) was incubated with active MMP-9 (4 nM) in assay buffer (50 mM Tris at pH 7.5,        
10 mM CaCl2, 1 µM ZnCl2, and 150 mM NaCl) in a sand bath maintained at 37
0
C. An aliquot of 
the reaction mixture was removed at various time intervals [0.5, 1, 2, 6, and 12 hour(s)] and 
mixed with an equal volume of the matrix. The mixture was spotted on a metal MALDI target 
plate and analyzed using the Bruker Reflex III MALDI-TOF mass spectrometer. The following 
matrices were used: 1M 2,5-dihydroxybenzoic acid in acetonitrile/HPLC grade water (50/50 
v/v%) containing 0.1% formic acid, and 0.1 M α-cyano-4-hydroxycinnamic acid in 
acetonitrile/HPLC grade water (50/50 v/v%) containing 0.1% formic acid. 
2.2.8 (A) LC-MS for monitoring the in situ enzymatic activity of MMP-9 in eppendorf vials 
 A Hewlett Packard 1100 series HPLC (Palo Alto, CA, USA) with a Bruker Esquire 2000 
quadrupole ion trap electrospray ionization mass spectrometer (Billerica, MA, USA) was used in 
the positive ion mode. A bio wide pore C18 reverse phase column (15 cm × 4.6 mm) (Supelco, 
St. Louis, MO, USA) was used for the separation of analytes. Solvent A contained 0.1% formic 
acid in water and solvent B contained 0.1% formic acid in acetonitrile.  The mobile phase flow 
rate was 0.8 mL/min with a 5-100% gradient of 0.1% formic acid in acetonitrile over 60 minutes.  
Samples were injected using an autoinjector with an injection volume of 10 µL. The              
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mass spectrometer was operated in positive ion mode with 2.1 × 10
5
 Pa nebulizing pressure (N2), 
and 12 mL/min flow of drying gas at a temperature of 300
0
 C. 
2.2.8 (B) MALDI-TOF MS for monitoring the in situ enzymatic activity of MMP-9 in 
eppendorf vials 
DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg (50 µM) was incubated with active MMP-9       
(530 pM) in assay buffer (50 mM Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and 150 mM NaCl) 
in a sand bath maintained at 37
0
C (Figure 2.1). Negative control was performed with 50 µM 
GM-6001. An aliquot of the reaction mixture was removed at various time intervals [0.5, 1, 2, 6, 
12, and 24 hour(s)] and mixed with the matrix. The mixture was spotted on a metal MALDI 
target plate and analyzed using the Bruker Reflex III MALDI-TOF mass spectrometer. The 
following matrices were used: 1M 2,5- dihydroxybenzoic acid in acetonitrile/HPLC grade water 
(50/50 v/v%) containing 0.1% formic acid, and 0.1 M α-cyano-4-hydroxycinnamic acid in 
acetonitrile/HPLC grade water (50/50 v/v%) containing 0.1% formic acid. 
2.2.9 MALDI-TOF imaging MS for monitoring the in situ localization of MMP-9 enzymatic 
activity on ITO-coated glass slides 
The localization of active MMP-9 on ITO-coated glass slides was studied using MALDI-
TOF imaging MS. The matrices were: 1M 2,5-dihydroxybenzoic acid in acetonitrile/HPLC grade 
water (50/50 v/v%) containing 0.1% formic acid, and 0.1 M α-cyano-4-hydroxycinnamic acid in 
acetonitrile/HPLC grade water (50/50 v/v%) containing 0.1% formic acid. The ITO-coated glass 
slides were marked with white-out. Digital images of the sample areas on the slides were 
acquired using the scanner of a HP Deskjet F4240 All-in-one printer at a resolution of 600 ppi 
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(Hewlett-Packard Company, Palo Alto, CA, USA). The matrix solution was sprayed over the 
dried sample area using an in house-built nebulizer. The spray distance (marked with a ruler) was 
optimized to avoid excessive wetting of tissue sections, resulting in delocalization of analytes. 
Multiple spray cycles of 150-200 µL were performed on a sample area from a distance of 25 cm. 
The total volume of the matrix solution per sample area was 1.5 mL. The sample areas on the 
glass slide were air-dried at room temperature for 5 minutes in between the spraying cycles. The 
time scale of the matrix spraying and drying process was 30 minutes. The white-out dots were 
used to teach the software for selecting the imaging area by providing positional information. 
a. Predigested (substrate + active MMP-9) mixture on ITO-coated glass slide  
A uniform layer of 50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg was applied to ~1 cm
2 
square area on the glass slide and dried at 37
0
C in an oven for 30 minutes. A predigested mixture 
of [(50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg + 530 pM active MMP-9), 37
0
 C, 24 hours 
incubation] was applied at the center of the 1 cm
2 
square area and dried at 37
0
C in an oven for 30 
minutes. Peptide calibration standard II (2 µL) from Bruker Daltonics Inc. (Billerica, MA, USA) 
was spotted beside the 1 cm
2 
square area and allowed to dry at room temperature for 5 minutes. 
After matrix spraying and drying, sample areas were analyzed using the MALDI-TOF mass 
spectrometer. 
b. Incubation on ITO-coated glass slide with active MMP-9 
A uniform layer of 50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg was applied to ~1 cm
2
 
square area on the glass slide. Active MMP-9 (530 pM) was applied at the center of the 1 cm
2 
square area. The glass slide was incubated in a humidity chamber at 37
0
C for 24 hours. Peptide 
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calibration standard II (2 µL) from Bruker Daltonics was spotted beside the 1 cm
2 
square area. 
The matrix solution was sprayed over the sample area of interest. Sample areas were analyzed 
using the MALDI-TOF mass spectrometer. 
2.3 Results and Discussion 
2.3.1 MALDI-TOF imaging MS for monitoring the in situ localization of trypsin enzymatic 
activity on ITO-coated glass slides 
Trypsin digested 20 µM cytochrome c at the triangular region on the 1 cm
2 
square area.            
Figure 2.2 (A) shows the undigested cytochrome c around the 1 cm
2 
square area. The matrix 
spraying process resulted in delocalization of analytes in the sample area. The MALDI-TOF 
mass spectrum of cytochrome c is shown in Figure 2.2 (B). The MALDI-TOF mass spectrum of 
cytochrome c digestion products by trypsin is shown in Figure 2.2 (C).  
The sequence of bovine cytochrome c was obtained from www.expasy.org: 
GDVEK GKKIF VQKCA QCHTV EKGGK HKTGP NLHGL FGRKT GQAPG FSYTD 
ANKNK GITWG EETLM EYLEN PKKYI PGTKM IFAGI KKKGE REDLI AYLKK ATNE  
 The sequence of bovine cytochrome c was used in SequenceEditor software          
(Bruker Daltonik, Bremen, Germany) to generate the theoretical molecular masses of trypsin 
digestion fragments (Table 2.1). All the fragments except CAQCHTVEK (m/z 1018.4) were 
observed in the mass spectrum. The protonated peak at m/z 1168.8 (TGPNLHGLFGR) was 
considered to represent the tryptic digestion fragment for generating the MALDI-TOF MS 
27 
 
image. The results of this experiment indicated the possibility of imaging localized MMPs 
activity on ITO-coated glass slides using MALDI-TOF imaging MS. 
Range [MH]
+
 Sequence 
[1-5] 547.3 GDVEK 
[9-13] 634.4 IFVQK 
[14-22] 1018.4 CAQCHTVEK 
[28-38] 1168.6 TGPNLHGLFGR 
[40-53] 1456.7 TGQAPGFSYTDANK 
[74-79] 678.4 YIPGTK 
[80-86] 779.4 MIFAGIK 
[92-99] 964.5 EDLIAYLK 
 
Table 2.1 Theoretical molecular masses of bovine cytochrome c digestion by trypsin  
(m/z 500 - m/z 1600) 
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Figure 2.2 (A) MALDI-TOF MS image of in situ digestion on ITO-coated glass slide showing 
localized trypsin activity at the triangular region (37
0 
C, 30 minutes) 
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Figure 2.2 (B) MALDI-TOF mass spectrum of cytochrome c (# of laser shots accumulated = 
300)     
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Figure 2.2 (C) MALDI-TOF mass spectrum of cytochrome c digestion products by trypsin      
(# of laser shots accumulated = 300) 
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2.3.2 Zymography 
 Figure 2.3 confirms the activation of 94 kDa pro MMP-9 by APMA in to 84 kDa active 
MMP-9 visible as clear zones against a blue background.  
 
Figure 2.3 Activation of pro MMP-9 by APMA 
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2.3.3 Fluorescence studies with QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys    
(5-FAM)-NH2 
Figure 2.4 shows the fluorescence measurements of enzymatic reaction of active MMP-9 
(4 nM) with 10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2. The 
substrate showed negligible background fluorescence signal in the absence of active MMP-9. 
The results indicated that MMP-9 activity assay could be performed with this FRET substrate. 
 
Figure 2.4 Fluorescence measurements of enzymatic reaction of active MMP-9     (4 nM) with 
10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 at 37
0
 C 
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2.3.4 MALDI-TOF MS studies with QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-
Lys(5-FAM)-NH2 
Figures 2.5 (A) and 2.5 (B) show the mass spectra of 10 µM QXL
TM
 520-Pro- Leu-Gly-
Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 substrate in DHB (1M 2,5- dihydroxybenzoic acid 
in acetonitrile/HPLC grade water (50/50 v/v%) containing 0.1% formic acid) and CHCA        
(0.1 M α-cyano-4-hydroxycinnamic acid in acetonitrile/HPLC grade water (50/50 v/v%) 
containing 0.1% formic acid) matrix, respectively. The mass spectra did not show intense 
[M+H]
+
 peak for the substrate at m/z 1744. However, an intense peak at m/z 1372 was observed 
representing the loss of (5-FAM and NH, CH2 groups of arginine). The QXL
TM
 520 and 5-FAM 
modifications at the N- and C-terminus could be responsible for the fragmentation of the 
substrate. 
Figures 2.5 (C) and 2.5 (D) show the mass spectra of [(10 µM QXL
TM 
520- Pro-Leu-Gly-
Cys(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 + 4 nM active MMP-9), 37
0
C, 12 hours incubation] 
in DHB and CHCA matrix, respectively. The fragmentation products at m/z 853 and m/z 907 
representing the enzymatic activity of MMP-9 on QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-
D-Arg-Lys (5-FAM)-NH2 were not observed. This could be either because the product ions 
underwent extensive fragmentation or had lower ionization efficiencies. Hence, this longer 
wavelength FRET substrate was not used for imaging the activity of MMPs using MALDI-TOF 
MS. 
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Figure 2.5 (A) MALDI-TOF mass spectrum of 10 µM QXL
TM 
520-Pro-Leu-Gly-Cys(Me)~His-
Ala-D-Arg-Lys-(5-FAM)-NH2 in DHB matrix(# of laser shots accumulated = 300) 
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Figure 2.5 (B) MALDI-TOF mass spectrum of 10 µM QXL
TM 
520-Pro-Leu-Gly- 
Cys(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 in CHCA matrix (# of laser shots         
accumulated = 300) 
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Figure 2.5 (C) MALDI-TOF mass spectrum of [(10 µM QXL
TM
 520-Pro-Leu-Gly-Cys 
(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 + 4 nM active MMP-9), 37
0
C, 12 hours incubation] in 
DHB matrix (# of laser shots accumulated = 1000) 
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Figure 2.5 (D) MALDI-TOF mass spectrum of [(10 µM QXL
TM
 520-Pro-Leu-Gly-
Cys(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 + 4 nM active MMP-9), 37
0
C, 12 hours incubation] 
in CHCA matrix (# of laser shots accumulated = 1000) 
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2.3.5 (A) LC-MS for monitoring the in situ enzymatic activity of MMP-9 in eppendorf vials 
 Figure 2.6 (A) shows the LC chromatogram of the (substrate + active MMP-9) digest 
(37
0
C, 24 hours of incubation) analyzed by LC-ESI-MS. ESI-MS spectra shows [M+H
+
] peaks 
for the substrate at m/z 1012 [Figure 2.6 (B)], and MMP-9 digestion products at m/z 452 [Figure 
2.6 (C)] and m/z 579 [Figure 2.6 (D)].  
 
Figure 2.6 (A) LC chromatogram of the (substrate + active MMP-9) digest                           
(37
0
C, 24 hours of incubation) 
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       Figure 2.6 (B) ESI-MS spectrum of MMP-9 substrate, DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg 
 
Figure 2.6 (C) ESI-MS spectrum of MMP-9 digestion product, DNP-Pro-Leu-Gly 
 
Figure 2.6 (D) ESI-MS spectrum of MMP-9 digestion product, Met-Trp-Ser-Arg 
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2.3.5 (B) MALDI-TOF MS for monitoring the in situ enzymatic activity of MMP-9 in 
eppendorf vials 
QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys-(5-FAM)-NH2 was not MS-
compatible and therefore MMP-9 activity assay was performed with DNP-Pro-Leu-Gly~Met-
Trp-Ser-Arg. Figures 2.7 (A) and 2.7 (B) show the mass spectra of 50 µM DNP-Pro-Leu-
Gly~Met-Trp-Ser-Arg substrate in CHCA and DHB matrix, respectively. The DNP modification 
in the N-terminus of the substrate could have caused the substrate to undergo fragmentation. The 
mass spectrum of the substrate in CHCA matrix had an intense [M+H]
+
 peak at m/z 1012. The 
mass spectrum of the substrate in DHB matrix had an intense peak at m/z 775 representing the 
ion formed by the loss of the DNP group and the pyrrolidine ring of proline in the N-terminus of 
the substrate.  
 It was possible to monitor one of the hydrolysis products (m/z 579) of MMP-9 enzymatic 
activity on the FRET substrate after 12 hours of incubation at 37
0
C [Figures 2.7 (C) and 2.7 (D)]. 
“LIFT” technique was used to obtain MS/MS data from the m/z 579 fragment for confirmation 
(Figure 2.8). The product peak at m/z 579 was not observed in the negative control sample 
indicating that GM-6001 blocked the activity of MMP-9.  
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Figure 2.7 (A) MALDI-TOF mass spectrum of 50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg in 
CHCA matrix (# of laser shots accumulated = 300) 
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Figure 2.7 (B) MALDI-TOF mass spectrum of 50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg in 
DHB matrix (# of laser shots accumulated = 1000) 
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Figure 2.7 (C) MALDI-TOF mass spectrum of product (Met-Trp-Ser-Arg), m/z 579 in CHCA 
matrix (# of laser shots accumulated = 1000) 
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Figure 2.7 (D) MALDI-TOF mass spectrum of product (Met-Trp-Ser-Arg), m/z 579 in DHB 
matrix (# of laser shots accumulated = 1000) 
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Figure 2.8 MALDI-TOF MS/MS spectrum of the product (m/z 579) obtained using the “LIFT” 
technique 
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2.3.6 MALDI-TOF imaging MS for monitoring the in situ localization of MMP-9 enzymatic 
activity on ITO-coated glass slides 
The substrate fragment at m/z 775 (substrate-DNP group-pyrrolidine ring of proline) was 
considered to represent the undigested substrate in all the in situ imaging experiments. It was 
found that α-cyano-4-hydroxycinnamic acid (0.1 M in acetonitrile/HPLC grade water (50/50 
v/v%) containing 0.1% formic acid was not a suitable matrix for the spraying method. The 
substrate fragment peak at m/z 775, and one of the product peaks at m/z 579 were not uniformly 
observed throughout the sample area. The other matrix, 1M 2,5-dihydroxybenzoic acid in 
acetonitrile/HPLC grade water (50/50 v/v%) containing 0.1% formic acid, produced a 
homogeneous layer with the sample as evidenced by the uniformity in the distribution of the 
substrate fragment peak at m/z 775, and one of the product peaks at m/z 579 throughout the 
sample area. 
a. Predigested (substrate + active MMP-9) mixture on ITO-coated glass slide 
When DHB matrix was sprayed from the nebulizer at a distance of 20 cm from the glass 
slide and with 250-300 µL multiple spray cycles per sample area, the spraying process resulted 
in delocalization of analytes in the sample area [Figure 2.9 (A)].  
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Figure 2.9 (A) MALDI-TOF MS image of predigested (substrate + active MMP-9)  mixture on 
the ITO-coated glass slide (37
0 
C, 24 hours of incubation) with a 600 × 600 µm
2
 raster 
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b. Incubation on ITO-coated glass slide with active MMP-9 
Active MMP-9 (530 pM) digested 50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg at the 
center of the 1 cm
2 
square area. Undigested DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg represented by 
m/z 775 is visible around the 1 cm
2 
square area [Figure 2.9 (B)]. 
 Optimizing the spraying distance to 25 cm and the volume range of multiple spray cycles 
to 150–200 µL resulted in homogeneous distribution of the DHB matrix.  
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Figure 2.9 (B) MALDI-TOF MS image of in situ digestion on the ITO-coated glass slide with 
active MMP-9 (37
0 
C, 24 hours incubation) with a 600 × 600 µm
2
 raster 
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2.4 Conclusions 
LC-ESI MS clearly showed the MMP-9 hydrolysis products at m/z 452 and m/z 579. 
However, MALDI-TOF MS did not show the hydrolysis product at m/z 452. It was possible to 
get an image of localized MMP-9 activity on DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg in situ by 
monitoring the hydrolysis product at m/z 579 using MALDI imaging MS. The results also 
indicated that DHB might be a better matrix for ex vivo tissue imaging studies. The initial 
spraying trials resulted in delocalization of analytes in the sample area. In order to avoid this, the 
spraying distance and the volume required for multiple spray cycles for the matrix solution were 
optimized for the in situ imaging studies. Matrix selection and deposition determined the quality 
of the MS image. This knowledge was applied when dealing with tissue samples for ex vivo 
imaging studies described in Chapter III. 
Higher sensitivity was obtained with a metal MALDI target when compared to the ITO-
coated glass slide. However, ITO-coated glass slides are convenient for transferring thin tissue 
sections from the cryostat during sample preparation for the ex vivo tissue imaging studies. 
Hence, in situ imaging studies to monitor localized MMP-9 activity was performed with DNP-
Pro-Leu-Gly~Met-Trp-Ser-Arg on ITO-coated glass slides. 
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3. EX VIVO STUDIES TO IMAGE THE SPATIAL LOCALIZATION OF ACTIVE  
MMP-2 AND MMP-9 
 
3.1 Introduction 
In this chapter, DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg was used for the ex vivo detection of 
active MMP-2 and MMP-9 in the FBR-induced tissue samples using MALDI-TOF MS. DNP-
Pro-Leu-Gly~Met-Trp-Ser-Arg could not be used for fluorescence imaging because of the high 
background resulting from the illumination of cells with the UV light. QXL
TM
 520-Pro-Leu-Gly-
Cys(Me)~His-Ala-D-Arg-Lys(5-carboxyfluorescein or 5-FAM)-NH2, a longer wavelength FRET 
substrate was used for fluorescence imaging studies.
67
 When the peptide is intact, the 
fluorescence of 5-FAM (donor) is quenched by QXL
TM
 520 (acceptor) through FRET. Upon 
cleavage by MMPs in to two separate fragments, the fluorescence of 5-FAM is recovered and 
can be detected at an excitation wavelength of 490 nm and an emission wavelength of 520 nm.  
3.2 Experimental section 
3.2.1 Chemicals 
MMP-9 (recombinant rat proenzyme, 94 kDa monomer, specific activity > 710 
picomoles/min/µg) was purchased from R & D Systems Inc. (Minneapolis, MN, USA). DNP-
Pro-Leu-Gly~Met-Trp-Ser-Arg, p-aminophenylmercuricacetate, GM-6001 (Galardin or N-[(2R)-
2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide, a broad-
spectrum MMPs inhibitor), ethanol, methanol, isopropanol, acetonitrile, and DMSO were 
purchased from EMD chemicals (Gibbstown, NJ, USA).  Formic acid and HPLC grade water 
were purchased from Alfa Aesar (Ward Hill, MA, USA). Matrix chemicals,                            
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2,5–dihydroxybenzoic acid, and α-cyano-4-hydroxycinnamic acid were purchased from Sigma-
Aldrich (St. Louis, MO,USA). QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys            
(5-carboxyfluorescein or 5-FAM)-NH2 specific for MMPs-1, -2, -8, - 9, -12, -13 and -14 was 
purchased from Anaspec (Fremont, CA, USA). Stock solutions of DNP-Pro-Leu-Gly~Met-Trp-
Ser-Arg and QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 were 
prepared in dimethyl sulfoxide (DMSO). Further dilutions were carried out with the assay buffer 
(50 mM Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and 50 mM NaCl). 
Ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (100X) was 
purchased from Calbiochem (San Diego, CA, USA). 1X solution contains 500 µM 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 150 nM aprotinin, 1 µM N-
(trans-Epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64), protease inhibitor, and 1 µM 
leupeptin, hemisulfate. This protease inhibitor cocktail inhibits serine and cysteine proteases, but 
not metalloproteases.
68
 The 100X EDTA-free protease inhibitor cocktail was diluted to 1X 
concentration with HPLC-grade water. 
Indium tin oxide (ITO)-coated glass slides were purchased from Bruker Daltonics Inc. 
(Billerica, MA, USA). Glass coplin staining jars with polypropylene screw cap were purchased 
from Wheaton science products (Millville, NJ, USA). Tissue-Tek O.C.T. compound was 
purchased from Sakura Finetek USA, Inc. (Torrance, CA, USA). 
3.2.2 Animals 
Male Sprague-Dawley rats (260 g to 290 g) were purchased from Harlan laboratories Inc. 
(Madison, WI, USA) and used in this study. 
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3.2.3 Biomaterial implantation procedure 
Rats were housed in a facility with a 12-hour on/off light cycle and had access to food 
and water ad libitum. All animal experiments were approved by the University of Arkansas 
animal care committee. Animals were anesthetized with 5% isoflurane (induction) followed by 
2% isoflurane (maintenance) inhalation in combination with O2. Under aseptic conditions, an 
incision ~1 cm in length was made on each side of the midline along the back of the rat. A 
subcutaneous pocket was created from each incision by blunt dissection. A microdialysis probe 
(CMA Microdialysis, North Chelmsford, MA, USA) with a polyethersulfone (PES) membrane 
was implanted into each pocket. Incisions at the implant site were sealed with Vetbond tissue 
adhesive (3M Animal Care Products, St. Paul, MN, USA). Following implantation, rats were 
returned to housing for 24 hours. After 24 hours, the rats were euthanized by CO2 asphyxiation. 
Control tissues at a distance of 2 cm from the implants, and the tissues with the implants were 
cut into 2 cm by 2 cm blocks using sterile scalpel blades.
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3.2.4 Tissue sample preparation 
After dissection, tissue samples were loosely wrapped in aluminum foil, followed by 
immediate snap-freezing in liquid nitrogen. Samples were stored at -80
0
 C until needed for up to 
5 months. The tissue sample was maintained at the desired orientation on the cutting block by 
using optimum cutting temperature (O.C.T.) polymer. However, the tissue surface was free of 
the polymer. A thin frozen section of the tissue (20 µm) was cut at -21
0
 C using a Leica CM 
3050 S cryostat (Leica Microsystems GmbH, Wetzlar, Germany). Sections were thaw-mounted 
onto precooled (-20
0
 C) normal and ITO - coated glass slides and were stored at -80
0
 C until 
analysis. Tissue sections were dehydrated in a vacuum desiccator for 30 minutes. The ITO-
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coated glass slides were marked with white BIC wite-out shake-N squeeze correction pen (BIC 
USA Inc., Shelton, CT, USA). Digital images of the tissue sections on the target plate were 
acquired using the scanner of a HP Deskjet F4240 All-in-one printer at a resolution of 600 ppi 
(Hewlett-Packard Company, Palo Alto, CA, USA). The white-out dots were used to teach the 
software for selecting the imaging area by providing positional information. 
3.2.5 MALDI-TOF MS system 
Mass spectrometric analyses were performed in the reflectron, positive mode at 25 kV 
accelerating potential on a Reflex III MALDI-TOF mass spectrometer equipped with a pulsed 
nitrogen laser working at 337 nm at a laser repetition rate of 8.1 Hz (Bruker Daltonik, Bremen, 
Germany). External calibration was performed using a solution of peptide calibration standard II 
(Bruker Daltonics Inc., Billerica, MA, USA) containing angiotensin II, angiotensin I, substance 
P, bombesin, ACTH clip 1-17, ACTH clip 18-39, and somatostatin 28, and DHB matrix solution 
{[M+H]
+
: 1046.5, 1296.7, 757.4, 1347.7, 1619.8, 2093.1, 2465.2, 3147.5, and 137.0}. MS/MS 
spectra were obtained using the “LIFT” technique in a Bruker Ultraflex II MALDI-TOF/TOF 
mass spectrometer (Bruker Daltonik, Bremen, Germany). 
Spectral acquisition from each spot was achieved using Bruker Flexanalysis 2.4 software. 
The substrate fragment at m/z 775 was considered to represent the undigested substrate. Mass 
spectral data sets were acquired using the Fleximaging software (Bruker Daltonik, Bremen, 
Germany) with a raster width of 600 µm. Each pixel composed of 300 individual laser shots 
collected in 50-shot increments form four positions within a single spot. Molecular images were 
visualized using the Fleximaging software.  
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3.2.6 Alcohol-based tissue washing 
The solvents used in this study were selected based on their efficacy for lipid 
solubilization and enzyme activity preservation.
55,70
 The following solvents: 70/30 v/v% 
ethanol/water, 80/20 v/v% methanol/water, and isopropanol were used for tissue washing.  
Tissue sections were washed by gentle immersing in 70 mL of solvent placed in a glass coplin 
jar (Wheaton Science Products, Millville, NJ, USA) at 4
0
 C for 12 hours. Care was taken to 
ensure that the coplin jars were undisturbed to prevent diffusion of the endogenous molecules on 
the tissue surface.
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3.2.7 Matrix selection and deposition 
The three commonly used matrices for imaging MS studies are sinapinic acid, 2,5-
dihydroxybenzoic acid, and α-cyano-4-hydroxycinnamic acid. Sinapinic acid was not considered 
for this research as it is the matrix of choice for protein analysis in tissue sections. The matrices, 
α-cyano-4-hydroxycinnamic acid and 2,5-dihydroxybenzoic acid, were selected since they are 
well known for  highest sensitivity in peptide analysis and for good signal intensity 
respectively.
48
 The matrices were dissolved in acetonitrile/HPLC grade water (50/50 v/v%) 
containing 0.1% formic acid.                        
High resolution tissue imaging requires homogeneous matrix deposition without inducing 
lateral migration of analytes.
49
 The matrix solution was sprayed over the tissue sections using a 
home-built nebulizer. The spray distance was optimized to avoid excessive wetting of tissue 
sections marked by dripping of matrix solution from the tissue sections, resulting in 
delocalization of analytes. Multiple spray cycles of 150-200 µL were performed on a single 
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tissue section from a distance of about 25 cm. The total volume of the matrix solution per tissue 
section was 1.5 mL. Tissue sections on the glass slide were air-dried at room temperature for 5 
minutes in between the spraying cycles. The time scale of the matrix spraying and drying process 
was 30 minutes.  
3.2.8 Fluorescence imaging system 
Fluorescence imaging studies were performed using an Olympus BH2-RFCA (reflected 
light fluorescence attachment) microscope. 
3.2.9 Imaging active MMP-2 and MMP-9 localization ex vivo using FRET substrate 
A. MALDI-TOF imaging MS 
a. Matrix selection 
 The product peak at m/z 579 was observed in fewer places in α-cyano-4-
hydroxycinnamic acid matrix when compared to 2,5-dihydroxybenzoic acid matrix. Hence, DHB 
was selected as the matrix for all MALDI-TOF imaging MS experiments. 
b. Unwashed control tissue  
Predigested mixture of [(50 µM DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg + 530 pM active 
MMP-9), 37
0
 C, 24 hours incubation] was applied to the unwashed control tissue on ITO-coated 
glass slide. Peptide calibration standard II (2 µL) from Bruker Daltonics was spotted beside the 
tissue section. After acquiring the digital image in a scanner and spraying with DHB matrix, the 
tissue section was analyzed using the MALDI-TOF mass spectrometer. 
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c. Ethanol washed control tissue  
Ethanol wash is recommended to remove phospholipids, physiological salts, and to fix 
proteins to increase ion yield in tissue samples.
72
 The effect of 70/30 v/v% ethanol/water wash 
on the activity of MMPs was studied using fluorescence imaging studies. The results from these 
studies confirmed that the ethanol wash did not affect the activity of MMPs [Figure 3.8 (C)]. 
Hence, the same solvent system was selected and tested for its effect on MMPs activity and 
delipidation using MALDI-TOF imaging MS studies. 
A specific region of the control tissue on the ITO-coated glass slide was selected and the 
region was marked underneath the slide using liquid white-out. Active MMP-9 (530 pM) was 
added to the specific region (red circle). The slide was incubated in an oven at 37
0
 C for 15 
minutes and was subjected to 70/30 v/v% ethanol/water wash at 4
0
C for 12 hours followed by 
drying at room temperature for 15 minutes. The tissue was covered with assay buffer (50 mM 
Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and 50 mM NaCl) and was allowed to dry in an oven 
at 37
0
 C for 15 minutes. DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg (50 µM) was added to the red 
circular area and incubated in a humidity chamber at 37
0
C for 12 hours (Figure 3.2). After 
acquiring the digital image in a scanner and spraying with DHB matrix, the tissue section was 
analyzed using the MALDI-TOF mass spectrometer. 
d. Control tissue spiked with predigested (substrate + active MMP-9) 
The ITO-coated glass slide with the control tissue was immersed in 70/30 v/v% 
ethanol/water at 4
0
 C for 12 hours followed by drying at room temperature for 15 minutes. The 
tissue was covered with assay buffer (50 mM Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and   
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50 mM NaCl) and was allowed to dry to dry in an oven at 37
0
 C for 15 minutes. The tissue was 
spiked with predigested [(50 µM DNP-PLG~MWSR + 530 pM active MMP-9), 37
0 
C, 24 hours 
incubation]. After acquiring the digital image in a scanner and spraying with DHB matrix, the 
tissue section was analyzed using the MALDI-TOF mass spectrometer. 
e. Control tissue incubated with (substrate + active MMP-9) 
The ITO-coated glass slide with the control tissue was immersed in 70/30 v/v% 
ethanol/water at 4
0
 C for 12 hours followed by drying at room temperature for 15 minutes. The 
tissue was covered with assay buffer (50 mM Tris at pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, and   
50 mM NaCl) and was allowed to dry in an oven at 37
0
 C for 15 minutes. The tissue was 
incubated with [(50 µM DNP-PLG~MWSR + 530 pM active MMP-9)] in a humidity chamber at 
37
0 
C for 12 hours. After acquiring the digital image in a scanner and spraying with DHB matrix, 
the tissue section was analyzed using the MALDI-TOF mass spectrometer. 
f. Microdialysis probe implanted tissues incubated with substrate 
The ITO-coated glass slide with three microdialysis probe implanted tissues was 
immersed in 70/30 v/v% ethanol/water at 4
0
 C for 12 hours followed by drying at room 
temperature for 15 minutes. Tissues were covered with assay buffer (50 mM Tris at pH 7.5,      
10 mM CaCl2, 1 µM ZnCl2, and 50 mM NaCl) and were allowed to dry in an oven at 37
0
 C for 
15 minutes. The II tissue was incubated with (50 µM DNP-PLG~MWSR+ 1X protease inhibitor 
cocktail). No treatment (I tissue) and negative control treatment with [(50 µM DNP-
PLG~MWSR+ 1X protease inhibitor cocktail + 50 µM GM-6001), III tissue] were also 
performed. The slide was incubated in a humidity chamber at 37
0 
C for 24 hours. After acquiring 
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digital images in a scanner and spraying with DHB matrix, tissue sections were analyzed using 
the MALDI-TOF mass spectrometer. “LIFT” technique was used to obtain MS/MS data from the 
m/z 579 fragment for confirmation. 
ClinPro Tools software (Version 2.2, Bruker Daltonik GmbH, Bremen, Germany) was 
used for mass spectral data interpretation. The quick classifier algorithm for automatic peak 
detection only considered peaks with a signal to noise threshold of 5 with respect to the base 
peak. Individual peaks in the spectrum from three groups (no treatment, treatment, and negative 
control treatment) were aligned and peak intensities were analyzed for the m/z 579.0 peak.  
B. Fluorescence imaging 
Fluorescence imaging was initially used to check the effect of alcohol washing on the 
activity of MMPs. 10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 
was applied to the control tissue, and to the probe implanted tissue followed by incubation at   
37
0
 C in a humidity chamber for 12 hours. Negative control with GM-6001 was included. An 
EDTA-free protease inhibitor cocktail that prevents the hydrolysis of the substrate by proteinases 
other than MMPs was employed to validate the activity of MMPs.
73
 The tissues were examined 
under a fluorescence microscope. 
3.3 Results & Discussion 
A. MALDI-TOF imaging MS 
a. Unwashed control tissue 
Salts, lipids, and endogenous compounds on the tissue surface can result in “ion 
suppression” by preferentially capturing protons during the ionization process and appearing at 
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higher abundance in the spectrum thereby suppressing the signal of other molecules.
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Phospholipids in the analysis region (m/z 575 - m/z 579) presented significant challenges in this 
research by suppressing the product peak at m/z 579 indicating the necessity of an appropriate 
tissue washing procedure to remove interfering lipids (Figure 3.1).  
b. Ethanol washed control tissue  
MMP-9 activity was localized in the red circular area indicating that the 70/30 v/v% 
ethanol/water washing did not affect the activity of MMP-9 (Figure 3.2). The interferent 
phospholipids peaks were less intense and did not suppress the product peak at m/z 579 
indicating the delipidation efficiency of 70/30 v/v% ethanol/water. 
c. Control tissue spiked with predigested (substrate + active MMP-9) 
The 70/30 v/v% ethanol/water washed control tissue spiked with predigested MMP-9 
product mixture showed the undigested substrate fragment peak at m/z 775 and the product peak 
at m/z 579, confirming the delipidation efficiency of 70/30 v/v% ethanol/water (Figure 3.3). 
d. Control tissue incubated with (substrate + active MMP-9) 
The 70/30 v/v% ethanol/water washed control tissue incubated with (substrate + active 
MMP-9) mixture showed the undigested substrate fragment peak at m/z 775 and the product peak 
at m/z 579, reconfirming the delipidation efficiency of 70/30 v/v% ethanol/water (Figure 3.4).  
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e. Microdialysis probe implanted tissues incubated with substrate 
The substrate fragments at m/z 690 and m/z 775 were considered to represent the 
undigested substrate. The 70/30 v/v% ethanol/water washed microdialysis probe implanted tissue 
without any treatment had background peaks at m/z 690 and at m/z 775 in certain regions [Figure 
3.5 (A) (i)].  
The 70/30 v/v% ethanol/water washed microdialysis probe implanted tissue incubated 
with (50 µM DNP-PLG~MWSR + 1X protease inhibitor cocktail) showed the undigested 
substrate fragment peaks at m/z 690 and m/z 775 distributed all over the tissue. The product peak 
at m/z 579 was observed around the microdialysis probe indicating the localization of active 
MMP-2 and MMP-9 around the microdialysis probe [Figure 3.5 (A) (ii)].  
The 70/30 v/v% ethanol/water washed microdialysis probe implanted tissue incubated 
with (50 µM DNP-PLG~MWSR+ 1X protease inhibitor cocktail + 50 µM GM-6001) showed the 
undigested substrate fragment peaks at m/z 690 and at m/z 775 distributed all over the tissue. The 
product peak at m/z 579 was not observed around the microdialysis probe, thus validating the 
activity assay scheme [Figure 3.5 (A) (iii)]. 
The MALDI-TOF MS/MS image of 70/30 v/v% ethanol/water washed microdialysis 
probe implanted tissue incubated with (50 µM DNP-PLG~MWSR + 1X protease inhibitor 
cocktail) showed the localization of fragments from the unimolecular decomposition of the m/z 
579 peak around the microdialysis probe [Figure 3.6(A)]. Figure 3.6 (B) shows the MALDI-TOF 
MS/MS spectrum of the product (m/z 579) using the “LIFT” technique. 
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Using the ClinProTools analysis, P-value from Anderson-Darling test (0.0000357) 
clearly indicated that the peaks (m/z 579) included in the analysis were not normally distributed 
and thus non-parametric statistical tests are required (Table 3.1). Since the peaks were not 
normally distributed, the Kruskal-Wallis test was used to determine the significant difference 
between three group [no treatment, treatment, and negative treatment (GM-6001)] averages. 
Kruskal-Wallis test resulted in a P-value of 0.0638. The kruskal-wallis test will be highly 
significant (<0.05) only when all the 3 groups are significantly different from each other. Out of 
the 3 groups, two groups were not significantly different from each other. Hence, the P-value of 
0.0638 that shows a marginal difference among the 3 groups is acceptable. Figure 3.7 (A) and 
Figure 3.7 (B) compare all single spectra and average spectral intensities of m/z 579.0 peak for 
no treatment (green), treatment (red), and negative treatment (blue).  
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Figure 3.1 (A) Digital (L) and MALDI-TOF MS image of unwashed control tissue spiked with 
predigested [(50 µM DNP-PLG~MWSR-OH + 530 pM active MMP-9), 37
0 
C, 24 hours 
incubation] with a 600 × 600 µm
2
 raster 
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Figure 3.1 (B) MALDI-TOF mass spectrum of unwashed control tissue spiked with predigested 
[(50 µM DNP-PLG~MWSR-OH + 530 pM active MMP-9), 37
0 
C, 24 hours incubation] showing 
the distribution of lipids from m/z 575 – m/z 579 
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Figure 3.2 Digital (L) and MALDI-TOF MS image of localized MMP-9 activity at a specific 
region (red circle)  on 70/30 v/v% ethanol/water washed control tissue with a 600 × 600 µm
2
 
raster 
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Figure 3.3 Digital (L) and MALDI-TOF MS image (R) of 70/30 v/v% ethanol/water washed 
control tissue spiked with predigested [(50 µM DNP-PLG~MWSR + 530 pM active MMP-9), 
37
0 
C, 24 hours incubation] with a 600 × 600 µm
2
 raster 
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  Figure 3.4 Digital (L) and MALDI-TOF MS image (R) of 70/30 v/v% ethanol/water         
washed control tissue incubated with [50 µM DNP-PLG~MWSR + 530 pM active  MMP-9] at 
37
0
C for 12 hours with a 600 ×600 µm
2
 raster 
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Figure 3.5 Digital (Top) and MALDI-TOF MS (Bottom) image of 70/30 v/v% ethanol/water 
washed microdialysis probe implanted tissue: (i) without treatment, (ii) incubated with (50 µM 
DNP-PLG~MWSR + 1X protease inhibitor cocktail), and (iii) incubated with (50 µM DNP-
PLG~MWSR + 1X protease inhibitor cocktail + 50 µM GM-6001) [37
0 
C, 24 hours incubation] 
with a 600 × 600 µm
2
 raster 
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Figure 3.6 (A) Digital (Top) and MALDI-TOF MS/MS (Bottom) image of 70/30 v/v% 
ethanol/water washed microdialysis probe implanted tissue: (i) without treatment, (ii) incubated 
with (50 µM DNP-PLG~MWSR + 1X protease inhibitor cocktail), and (iii) incubated with        
(50 µM DNP-PLG~MWSR + 1X protease inhibitor cocktail + 50 µM GM-6001) [37
0 
C, 24 
hours incubation] with a 600 × 600 µm
2
 raster 
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Figure 3.6 (B) MALDI-TOF MS/MS spectrum of the product (m/z 579) using the “LIFT” 
technique 
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Figure 3.7 (A) Comparison of all single spectral peak intensities of m/z 579.0 peak showing 
significant difference between no treatment (green), treatment (red), and negative treatment 
(blue) [X-axis: m/z, Y-axis: Intensity (A.U.)] 
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Figure 3.7 (B) Comparison of average spectral intensities of m/z 579.0 peak showing significant 
difference between no treatment (green), treatment (red), and negative treatment (blue) [X-axis: 
m/z, Y-axis: Intensity (A.U.)] 
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Mass (m/z value) 579.0 
Difference between the maximal and minimal average peak area of 
all classes 
675.04 
P-value of Kruskal-Wallis test 0.0638 
P-value of Anderson-Darling test 0.0000357 
Peak area intensity of no treatment 3.47 
Peak area intensity of treatment 675.9 
Peak area intensity of negative control treatment 0.86 
Standard deviation of peak area average of no treatment 1.48 
Standard deviation of peak area average of treatment 88.93 
Standard deviation of peak area average of negative treatment) 0.21 
Coefficient of variation in % of no treatment 42.65 
Coefficient of variation in % of treatment 13.16 
Coefficient of variation in % of negative treatment 24.4 
 
Table 3.1 Peak statistic report using ClinProTools software 
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B. Fluorescence imaging 
The control tissue did not exhibit fluorescence when incubated with the FRET substrate. 
Alcohol washed microdialysis probe implanted tissues incubated with 10 µM QXL
TM
 520-Pro-
Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 exhibited fluorescence around the 
microdialysis probe indicating the localization of proteolytic activities around the microdialysis 
probe [Figure 3.8(A)]. Alcohol washed microdialysis probe implanted tissues incubated with    
(10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 + 50 µM       
GM-6001) did not block the fluorescence around the microdialysis probe indicating the 
localization of proteolytic activities not specific for MMPs around the probe [Figure 3.8 (B)].  
In order to validate the activity of MMPs, an EDTA-free protease inhibitor cocktail was 
employed to block the hydrolysis of the substrate by proteases other than MMPs for 70/30 v/v% 
ethanol/water washed tissue samples [Figure 3.8 (C)]. About 70% of the time, the tissue sample 
that did not receive any treatment did not show autofluorescence. GM-6001 did not completely 
block the activity of MMPs. 
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Figure 3.8 (A) Microdialysis probe implanted tissues incubated with 10 µM QXL
TM
 520-Pro-
Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 exhibited fluorescence  around the 
microdialysis probe indicating the localization of proteolytic activities around the probe 
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Figure 3.8 (B) Alcohol washed microdialysis probe implanted tissues incubated with (10 µM 
QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 + 50 µM GM-6001) did 
not block the fluorescence around the probe indicating the localization of proteolytic activities 
not specific for MMPs around the probe 
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Figure 3.8 (C) 70/30 v/v% ethanol/water washed microdialysis probe implanted tissues:  (i) 
without treatment, (ii) incubated with (10 µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-
Arg-Lys(5-FAM)-NH2 + 1X EDTA-free protease inhibitor  cocktail), and (iii) incubated with (10 
µM QXL
TM
 520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 + 1X EDTA-free 
protease inhibitor cocktail + 50 µM GM-6001) 
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3.4 Conclusions 
It was not possible to image the localized activity of MMP-2 and MMP-9 in unwashed 
tissue samples because of signal suppression by lipids. Fluorescence imaging studies indicated 
that alcohol washing did not completely remove the activity of MMPs. The use of ethanol as 
washing solvent for MALDI-IMS experiments did not completely remove the lipids. However, 
the signal suppression effects from interfering lipids were eliminated from the tissue sections to 
allow the imaging of MMPs activity. 
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4. SUMMARY AND FUTURE DIRECTIONS 
Most of the standard methods to study the localization of active enzymes in tissue 
samples rely on microscopy and staining/labeling techniques.
75
 Visualizing the spatial 
localization of enzymatic activity using imaging mass spectrometry (IMS) by monitoring the 
mass difference between the substrate and its product(s) is a novel technique that does not 
require labeling agents.  
However, the use of a labeled substrate might permit simultaneous fluorescence and mass 
spectrometry imaging on a tissue sample. The longer wavelength FRET substrate (λEx/λEm = 490 
nm/520 nm), QXL
TM 
520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2, used in this 
research was selected solely for this purpose to image the localization of active MMPs in the 
FBR-induced tissue samples.  
QXL
TM 
520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-NH2 was found to be 
an excellent candidate for fluorescence imaging. But, the MMP-9 activity assay performed with 
this substrate did not prove to be MS-compatible.   
On the other hand, the MMP-9 activity assay performed with a shorter wavelength FRET 
substrate (λEx/λEm = 280 nm/360 nm), DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg, was compatible with 
MS. This substrate could not be used for fluorescence imaging studies because of the strong 
interference from tissue autofluorescence. Hence two different FRET substrates, DNP-Pro-Leu-
Gly~Met-Trp-Ser-Arg and QXL
TM 
520-Pro-Leu-Gly-Cys(Me)~His-Ala-D-Arg-Lys(5-FAM)-
NH2, were used in this research for IMS and fluorescence imaging respectively.  
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The control tissue sample spiked with predigested (active MMP-9 + DNP-Pro-Leu-
Gly~Met-Trp-Ser-Arg) showed ion suppression from lipids indicating the need for an 
appropriate tissue washing procedure. Alcohols are well known for their delipidation efficiency. 
Gawlak et al. reported that a combined ethanol and methanol fixation of rat brain tissues at 4
0
 C 
for 6 hours did not negatively affect the activity of MMP-2 and MMP-9.
70
 A longer alcohol 
washing time of 12 hours was selected for this research to achieve efficient removal of lipids. 
Fluorescence imaging studies with alcohol washed tissue samples were performed to make sure 
that alcohol washing did not have a negative effect on enzymatic activity. The use of GM-6001 
as a negative control in fluorescence imaging studies showed the presence of proteolytic 
activities not specific for MMPs around the implanted microdialysis probe. Hence, an EDTA-
free protease inhibitor cocktail was used to block the activity of proteinases other than MMPs.  
Ex vivo tissue studies with DNP-Pro-Leu-Gly~Met-Trp-Ser-Arg and EDTA-free protease 
inhibitor cocktail revealed the possibility of visualizing the spatial localization of active MMP-2 
and MMP-9 in the microdialysis probe implanted tissue by monitoring the product formed at m/z 
579 using MALDI-TOF imaging MS. The imaging data was validated by using GM-6001, a 
broad spectrum MMPs inhibitor.  
The pixel size of an image is referred to as spatial resolution in IMS.
47
 The diameter of 
the laser beam is the limiting factor in achieving high spatial resolution in MALDI IMS. There is 
a trade-off between signal intensity and spatial resolution. MALDI IMS data are mostly reported 
with a pixel size of 50-500 µm. The spatial resolution used for data acquisition in MALDI IMS 
experiments determines the detail level of the images.
76
 In this research, the MALDI MS image 
was obtained at a spatial resolution of 600 µm without compromising the signal intensity. 
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Reduced data file size and data acquisition time were the advantages of low spatial resolution. 
The localization of active MMP-2 and MMP-9 in the microdialysis probe implanted area was 
clearly visible in the MALDI MS image.   
Fluorescence imaging gives a qualitative picture of MMPs activity. MALDI IMS can be 
made quantitative by considering the fact that the IMS signal is a direct measure of the relative 
abundance of the analyte.
77
 Quantitative information can be obtained by comparing the MALDI 
MS image of MMPs localization with that of control tissue spiked with known concentrations of 
the product (m/z 579). However, the challenge would be to achieve a homogeneous deposition of 
the product on the tissue surface that matches with the deposition of the substrate.  
The bioanalytical method developed in this research enabled the visualization of 
localized gelatinases (MMP-2 and MMP-9) activity at the implant site in ex vivo tissue samples. 
In the future, this approach can be extended to visualize the localization of several active MMPs 
at the implant site in ex vivo tissue samples. FRET substrates were used in this research only for 
the purpose of using fluorescence imaging as a complementary technique. However, a 
multiplexed assay to visualize the localization of several active MMPs is difficult to achieve in 
fluorescence imaging because of the limited number of fluorophores that can provide non-
overlapping emission bands for the products of MMPs activity. On the other hand, several non-
FRET synthetic substrates specific for MMPs of interest can be employed for imaging the 
localized MMPs activity during the foreign body response in ex vivo tissue samples. 
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